Catalyst Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Catalyst Pharmaceuticals CEO'su Rich Daly, Jan2024 tarihinde atandı, in görev süresi 1.08 yıldır. şirketin hisselerinin 0.22% doğrudan sahiptir ve bu hisselerin değeri € 5.52M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 12.1 yıldır.

Anahtar bilgiler

Rich Daly

İcra Kurulu Başkanı

US$14.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.1yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	12.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Rich Daly (63 yo)

1.1yrs

Görev süresi

US$14,076,923

Tazminat

Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard John Daly	President	1.1yrs	US$14.08m	0.22% € 5.5m
Steven Miller	Executive VP	15.3yrs	US$3.40m	0.78% € 19.3m
Gary Ingenito	Chief Medical & Regulatory Officer	9.7yrs	US$2.37m	0.051% € 1.3m
Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	4.7yrs	US$2.51m	0.019% € 472.8k
Michael Kalb	Executive VP	1.1yrs	Veri yok	0.0035% € 86.8k
Mary Coleman	VP & Head of Investor Relations	3.5yrs	Veri yok	Veri yok
Brian Elsbernd	Chief Compliance Officer & Chief Legal Officer	9yrs	US$353.27k	0.15% € 3.7m
Stanley Iyadurai	Senior Vice President of Medical Affairs & Drug Discovery	1.9yrs	Veri yok	Veri yok
Preethi Sundaram	Chief Strategy Officer	3.6yrs	US$1.70m	0.029% € 708.9k
Philip Schwartz	Corporate Secretary	no data	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: CN2 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard John Daly	President	10yrs	US$14.08m	0.22% € 5.5m
David Tierney	Independent Director	22.3yrs	US$370.99k	0.29% € 7.3m
Patrick McEnany	Co-Founder & Chairman	23.1yrs	US$2.15m	3.76% € 92.6m
Donald Denkhaus	Independent Director	10yrs	US$376.24k	0.41% € 10.1m
Charles O'Keeffe	Lead Independent Director	20.2yrs	US$397.24k	0.61% € 15.1m
Eugene Laska	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Fechtner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Brodie	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Molly Harper	Independent Director	3.7yrs	US$363.12k	0.0023% € 56.7k
Richard Silverman	Member of Scientific Advisory Board	14.3yrs	Veri yok	Veri yok
Tamar Thompson	Independent Director	1.8yrs	US$610.43k	0.0012% € 29.1k

12.1yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CN2 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/22 05:01
Gün Sonu Hisse Fiyatı	2025/02/21 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Catalyst Pharmaceuticals, Inc. 20 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joel Beatty	Baird
Jason Matthew Gerberry	BofA Global Research
Charles Duncan	Cantor Fitzgerald & Co.

Catalyst Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc

Executive VP recently sold €2.7m worth of stock

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Insider recently sold €380k worth of stock

COO & Chief Scientific Officer recently sold €528k worth of stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Recent updates

Catalyst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc

Catalyst Pharmaceuticals, Inc. Announces Sub- Licensee DyDo Pharma Launches Firapse®? in Japan

New minor risk - Share price stability

Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Third quarter 2024 earnings released: EPS: US$0.37 (vs US$0.29 loss in 3Q 2023)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Executive VP recently sold €2.7m worth of stock

New minor risk - Insider selling

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings released: EPS: US$0.20 (vs US$0.28 in 1Q 2023)

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Insider recently sold €380k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.67 (vs US$0.80 in FY 2022)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Investor sentiment improves as stock rises 17%

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold €528k worth of stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.22 profit in 3Q 2022)

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

New minor risk - Share price stability

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Investor sentiment deteriorates as stock falls 28%

First quarter 2023 earnings released: EPS: US$0.28 (vs US$0.13 in 1Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Full year 2022 earnings released: EPS: US$0.80 (vs US$0.38 in FY 2021)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Director recently sold €321k worth of stock

Third quarter 2022 earnings released: EPS: US$0.22 (vs US$0.10 in 3Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold €734k worth of stock

Co-Founder recently sold €16m worth of stock

Investor sentiment improved over the past week

Chief Accounting Officer recently sold €970k worth of stock

Chief Commercial Officer recently sold €198k worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.12 in 2Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Sep 19, 2022

Catalyst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022